Press
Vital Tears and Brightstar Therapeutics Announce Formation of Joint Medical Advisory Board to Advance Clinical Innovation in Ocular Surface Care
Click image to see the full release.
EyesonGlance Article
Recent interim findings evaluating the use of Brightstar Therapeutics’ proprietary anterior keratoplasty procedure support this solution-based approach for treating limbal stem cell deficiency (LSCD).
The data was presented by Joshua Hou, MD, Brightstar’s chief medical officer, during the Eye Bank Association of America and the Cornea Society’s Cornea and Eye Banking Forum in 2025..